How Genentech Could Be A New Threat For Biogen
The newest multiple sclerosis drug could be a boon for patients — and a threat to the multibillion-dollar business of Biogen Inc., the leading seller of MS treatments.
When regulators in March cleared the new drug, called Ocrevus and made by Genentech, it was the latest in a line of more than a dozen medicines that have emerged over the past two decades to treat MS. The neurological disease afflicts at least 400,000 Americans and more than 2.3 million people worldwide.
When regulators in March cleared the new drug, called Ocrevus and made by Genentech, it was the latest in a line of more than a dozen medicines that have emerged over the past two decades to treat MS. The neurological disease afflicts at least 400,000 Americans and more than 2.3 million people worldwide.